Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 3
2009 4
2010 1
2011 1
2013 1
2014 1
2018 3
2019 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy.
Berkeley RA, Steele LP, Mulder AA, van den Wollenberg DJM, Kottke TJ, Thompson J, Coffey M, Hoeben RC, Vile RG, Melcher A, Ilett EJ. Berkeley RA, et al. Among authors: ilett ej. Cancer Immunol Res. 2018 Oct;6(10):1161-1173. doi: 10.1158/2326-6066.CIR-18-0309. Epub 2018 Sep 12. Cancer Immunol Res. 2018. PMID: 30209061 Free article.
Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
Müller LME, Migneco G, Scott GB, Down J, King S, Askar B, Jennings V, Oyajobi B, Scott K, West E, Ralph C, Samson A, Ilett EJ, Muthana M, Coffey M, Melcher A, Parrish C, Cook G, Lawson M, Errington-Mais F. Müller LME, et al. Among authors: ilett ej. J Immunother Cancer. 2021 Mar;9(3):e001803. doi: 10.1136/jitc-2020-001803. J Immunother Cancer. 2021. PMID: 33741729 Free PMC article.
Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.
Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA. Samson A, et al. Among authors: ilett ej. Sci Transl Med. 2018 Jan 3;10(422):eaam7577. doi: 10.1126/scitranslmed.aam7577. Sci Transl Med. 2018. PMID: 29298869 Free PMC article.
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment.
Evgin L, Huff AL, Kottke T, Thompson J, Molan AM, Driscoll CB, Schuelke M, Shim KG, Wongthida P, Ilett EJ, Smith KK, Harris RS, Coffey M, Pulido JS, Pandha H, Selby PJ, Harrington KJ, Melcher A, Vile RG. Evgin L, et al. Among authors: ilett ej. Cancer Immunol Res. 2019 May;7(5):828-840. doi: 10.1158/2326-6066.CIR-18-0013. Epub 2019 Apr 2. Cancer Immunol Res. 2019. PMID: 30940643 Free PMC article.
Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.
Taggart D, Andreou T, Scott KJ, Williams J, Rippaus N, Brownlie RJ, Ilett EJ, Salmond RJ, Melcher A, Lorger M. Taggart D, et al. Among authors: ilett ej. Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1540-E1549. doi: 10.1073/pnas.1714089115. Epub 2018 Jan 31. Proc Natl Acad Sci U S A. 2018. PMID: 29386395 Free PMC article.
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity.
Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T, Thompson J, Morrison EE, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA. Prestwich RJ, et al. Among authors: ilett ej. Clin Cancer Res. 2008 Nov 15;14(22):7358-66. doi: 10.1158/1078-0432.CCR-08-0831. Clin Cancer Res. 2008. PMID: 19010851 Free PMC article.
16 results